Eric B. Haura, MD

Where You Are:
Eric B. Haura, MD

Senior Member

"Our lab uses proteomic tools to characterize kinase pathways and networks in cancer cells to discover novel therapeutic strategies using kinase inhibitors"

Office  (813) 745-6817

Education And Training
  • Clinical Fellow, Duke University Medical Center, 2000 - Hematology & Oncology
  • Research Fellow, Duke University Medical Center, 2000 - Genetics
  • Resident, Johns Hopkins Hospital, 1997 - Internal Medicine
  • MD, Duke University School of Medicine, 1994
  • BS, Johns Hopkins University, 1990 - Biomedical Engineering


Dr. Haura’s research focuses on tyrosine kinase signaling pathways and biomarkers in lung cancer.  His group demonstrated activity of SRC kinase inhibitors in lung cancer cells with activating EGFR mutations (Song et al, Cancer Res, 2006); subsequently they reported a strategy to comprehend signaling pathways active in lung cancer cells and targeted by dasatinib employing chemical proteomics to identify direct interacting proteins combined with immunoaffinity purification of tyrosine phosphorylated peptides corresponding to activated tyrosine kinases. They identified nearly 40 different kinase targets of dasatinib, including SFK members (LYN, SRC, FYN, LCK, YES), non-receptor tyrosine kinases (FRK, BRK, ACK), and receptor tyrosine kinases (ephrin receptors, DDR1, EGFR). Using drug resistant gatekeeper mutants, they showed that SFK kinases, particularly SRC and FYN as well as EGFR, are relevant targets for dasatinib action. The combined mass spectrometry-based approach provides a system-level view of dasatinib action in cancer cells and suggests both functional targets and rationale combinatorial therapeutic strategies. A phase I trial of the EGFR inhibitor erlotinib in combination with dasatinib was performed; side effects of the combination were tolerable, disease control and inhibition of plasma angiogenesis markers were observed, and two partial responses and one bone response were observed. Reductions in plasma VEGF and bFGF were observed, and reductions in VEGF correlated with disease control (supported by P50 CA119997). Future directions involve using protein-protein interaction mapping to define novel targets and biomarkers of kinase inhibitors.

  • Song L, Smith MA, Doshi P, Sasser K, Fulp W, Altiok S, Haura EB. Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer. J Thorac Oncol. 2014 Jul;9(7):974-982. Pubmedid: 24922005.
  • Yoshida T, Zhang G, Smith MA, Lopez AS, Bai Y, Li J, Fang B, Koomen JM, Rawal B, Fisher KJ, Chen YA, Kitano M, Morita Y, Yamaguchi H, Shibata K, Okabe T, Okamoto I, Nakagawa K, Haura EB. Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non-Small Cell Lung Cancer. Clin Cancer Res. 2014 Jun. Pubmedid: 24919575.
  • Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, Shyr Y, Camidge DR, Sequist LV, Glisson BS, Khuri FR, Garon EB, Pao W, Rudin C, Schiller J, Haura EB, Socinski M, Shirai K, Chen H, Giaccone G, Ladanyi M, Kugler K, Minna JD, Bunn PA. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. Jama. 2014 May;311(19):1998-2006. Pubmedid: 24846037.
  • Quinn GP, Haura EB, Murphy D. The ethical imperative of risk disclosure in research: the answer is always yes. Am J Bioeth. 2014 Apr;14(4):18-19. Pubmedid: 24730484.
  • Gray J, Haura EB, Chiappori A, Tanvetyanon T, Williams CC, Pinder-Schenk M, Kish JA, Kreahling JM, Lush RM, Neuger AM, Tetteh LF, Akar A, Zhao X, Schell MJ, Bepler G, Altiok S. A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors. Clin Cancer Res. 2014 Mar;20(6):1644-1655. Pubmedid: 24429877.
  • Donatelli SS, Zhou JM, Gilvary DL, Eksioglu EA, Chen X, Cress WD, Haura EB, Schabath MB, Coppola D, Wei S, Djeu JY. TGF-β-inducible microRNA-183 silences tumor-associated natural killer cells. Proc Natl Acad Sci U S A. 2014 Mar;111(11):4203-4208. Pubmedid: 24586048. Pmcid: PMC3964044.
  • Li J, Bennett K, Stukalov A, Fang B, Zhang G, Yoshida T, Okamoto I, Kim JY, Song L, Bai Y, Qian X, Rawal B, Schell M, Grebien F, Winter G, Rix U, Eschrich S, Colinge J, Koomen J, Superti-Furga G, Haura EB. Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms. Mol Syst Biol. 2014 Mar;9:705. Pubmedid: 24189400. Pmcid: PMC4039310.
  • Schabath MB, McIntyre J, Pratt C, Gonzalez LE, Munoz-Antonia T, Haura EB, Quinn GP. Healthcare providers' knowledge and attitudes about rapid tissue donation (RTD): phase one of establishing a rapid tissue donation programme in thoracic oncology. J Med Ethics. 2014 Feb;40(2):139-142. Pubmedid: 23557908.
  • Schneeberger VE, Luetteke N, Ren Y, Berns H, Chen L, Foroutan P, Martinez GV, Haura EB, Chen J, Coppola D, Wu J. SHP2E76K mutant promotes lung tumorigenesis in transgenic mice. Carcinogenesis. 2014 Feb. Pubmedid: 24480804.
  • Remsing Rix LL, Kuenzi BM, Luo Y, Remily-Wood E, Kinose F, Wright G, Li J, Koomen JM, Haura EB, Lawrence HR, Rix U. GSK3 Alpha and Beta Are New Functionally Relevant Targets of Tivantinib in Lung Cancer Cells. ACS Chem Biol. 2014 Feb;9(2):353-358. Pubmedid: 24215125.
  • Chiappori A, Williams C, Northfelt DW, Adams JW, Malik S, Edelman MJ, Rosen P, Van Echo DA, Berger MS, Haura EB. Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer. J Thorac Oncol. 2014 Jan;9(1):121-125. Pubmedid: 24346101.
  • McIntyre J, Pratt C, Pentz RD, Haura EB, Quinn GP. Stakeholder perceptions of thoracic rapid tissue donation: An exploratory study. Soc Sci Med. 2013 Dec;99:35-41. Pubmedid: 24355468. Pmcid: PMC3869974.
  • Haura EB, Smith MA. Signaling control by epidermal growth factor receptor and MET: rationale for cotargeting strategies in lung cancer. J Clin Oncol. 2013 Nov;31(32):4148-4150. Pubmedid: 24101046.
  • Schabath MB, Giuliano AR, Thompson ZJ, Amankwah EK, Gray J, Fenstermacher DA, Jonathan KA, Beg AA, Haura EB. TNFRSF10B polymorphisms and haplotypes associated with increased risk of death in non-small cell lung cancer. Carcinogenesis. 2013 Nov;34(11):2525-2530. Pubmedid: 23839018. Pmcid: PMC3810840.
  • Williams KA, Zhang M, Xiang S, Hu C, Wu JY, Zhang S, Ryan M, Cox AD, Der CJ, Fang B, Koomen J, Haura E, Bepler G, Nicosia SV, Matthias P, Wang C, Bai W, Zhang X. Extracellular signal-regulated kinase (ERK) phosphorylates histone deacetylase 6 (HDAC6) at serine 1035 to stimulate cell migration. J Biol Chem. 2013 Nov;288(46):33156-33170. Pubmedid: 24089523. Pmcid: PMC3829163.
  • Quinn GP, Murphy D, Pratt C, Muñoz-Antonia T, Guerra L, Schabath MB, Leon ME, Haura E. Altruism in terminal cancer patients and rapid tissue donation program: does the theory apply?. Med Health Care Philos. 2013 Nov;16(4):857-864. Pubmedid: 23539332. Pmcid: PMC3735793.
  • Creelan BC, Antonia S, Noyes D, Hunter TB, Simon GR, Bepler G, Williams CC, Tanvetyanon T, Haura EB, Schell MJ, Chiappori A. Phase II Trial of a GM-CSF-producing and CD40L-expressing Bystander Cell Line Combined With an Allogeneic Tumor Cell-based Vaccine for Refractory Lung Adenocarcinoma. J Immunother. 2013 Oct;36(8):442-450. Pubmedid: 23994887.
  • Chamrád I, Rix U, Stukalov A, Gridling M, Parapatics K, Müller AC, Altiok S, Colinge J, Superti-Furga G, Haura EB, Bennett KL. A miniaturized chemical proteomic approach for target profiling of clinical kinase inhibitors in tumor biopsies. J Proteome Res. 2013 Sep;12(9):4005-4017. Pubmedid: 23901793.
  • Kim JY, Beg AA, Haura EB. Non-canonical IKKs, IKKϵ and TBK1, as novel therapeutic targets in the treatment of non-small cell lung cancer. Expert Opin Ther Targets. 2013 Aug;17(10):1109-1112. Pubmedid: 23984985.
  • Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, Chiappori A, Tanvetyanon T, Pinder-Schenck M, Gray J, Haura E, Antonia S, Fischer JR. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2013 Jul;31(19):2404-2412. Pubmedid: 23690416. Pmcid: PMC3691357.
  • Kim JY, Welsh EA, Oguz U, Fang B, Bai Y, Kinose F, Bronk C, Remsing Rix LL, Beg AA, Rix U, Eschrich SA, Koomen JM, Haura EB. Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A. 2013 Jul;110(30):12414-12419. Pubmedid: 23836654. Pmcid: PMC3725062.
  • Hopewell EL, Zhao W, Fulp WJ, Bronk CC, Lopez AS, Massengill M, Antonia S, Celis E, Haura EB, Enkemann SA, Chen DT, Beg AA. Lung tumor NF-κB signaling promotes T cell-mediated immune surveillance. J Clin Invest. 2013 Jun;123(6):2509-2522. Pubmedid: 23635779. Pmcid: PMC3668836.
  • Song T, Yang L, Kabra N, Chen L, Koomen J, Haura EB, Chen J. The NAD+ Synthesis Enzyme Nicotinamide Mononucleotide Adenylyltransferase (NMNAT1) Regulates Ribosomal RNA Transcription. J Biol Chem. 2013 Jun;288(29):20908-20917. Pubmedid: 23737528.
  • Singh S, Trevino J, Bora-Singhal N, Coppola D, Haura E, Altiok S, Chellappan SP. EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. Mol Cancer. 2013 Mar;11:73. Pubmedid: 23009336. Pmcid: PMC3497614.
  • Guo J, Kim D, Gao J, Kurtyka C, Chen H, Yu C, Wu D, Mittal A, Beg AA, Chellappan SP, Haura EB, Cheng JQ. IKBKE is induced by STAT3 and tobacco carcinogen and determines chemosensitivity in non-small cell lung cancer. Oncogene. 2013 Jan;32(2):151-159. Pubmedid: 22330135.
  • Chen L, Chen DT, Kurtyka C, Rawal B, Fulp WJ, Haura EB, Cress WD. Tripartite motif containing 28 (Trim28) can regulate cell proliferation by bridging HDAC1/E2F interactions. J Biol Chem. 2012 Nov;287(48):40106-40118. Pubmedid: 23060449. Pmcid: PMC3504725.
  • Alexandrow MG, Song LJ, Altiok S, Gray J, Haura EB, Kumar NB. Curcumin: a novel Stat3 pathway inhibitor for chemoprevention of lung cancer. Eur J Cancer Prev. 2012 Sep;21(5):407-412. Pubmedid: 22156994. Pmcid: PMC3319490.
  • McBride A, Antonia SJ, Haura EB, Goetz D. Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature. J Pharm Pract. 2012 Aug;25(4):477-485. Pubmedid: 22550162.
  • Haura EB. From modules to medicine: How modular domains and their associated networks can enable personalized medicine. FEBS Lett. 2012 Aug;586(17):2580-2585. Pubmedid: 22575759. Pmcid: PMC4084654.
  • Xiong H, Lee RJ, Haura EB, Edwards JG, Dynan WS, Li S. Intranuclear delivery of a novel antibody-derived radiosensitizer targeting the DNA-dependent protein kinase catalytic subunit. Int J Radiat Oncol Biol Phys. 2012 Jul;83(3):1023-1030. Pubmedid: 22138455. Pmcid: PMC3698569.
  • Simon GR, Schell MJ, Begum M, Kim J, Chiappori A, Haura E, Antonia S, Bepler G. Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis. Cancer. 2012 May;118(9):2525-2531. Pubmedid: 22028294. Pmcid: PMC3270127.
  • Bai Y, Li J, Fang B, Edwards A, Zhang G, Bui M, Eschrich S, Altiok S, Koomen J, Haura EB. Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors. Cancer Res. 2012 May;72(10):2501-2511. Pubmedid: 22461510.
  • Haura EB, Sacco R, Li J, Müller AC, Grebien F, Superti-Furga G, Bennett KL. Optimisation of Downscaled Tandem Affinity Purifications to Identify Core Protein Complexes. J Integr OMICS. 2012 May;2(1):55-68. Pubmedid: 24077984.
  • Li R, Martin MP, Liu Y, Wang B, Patel RA, Zhu JY, Sun N, Pireddu R, Lawrence NJ, Li J, Haura EB, Sung SS, Guida WC, Schonbrunn E, Sebti SM. Fragment-based and structure-guided discovery and optimization of rho kinase inhibitors. J Med Chem. 2012 Mar;55(5):2474-2478. Pubmedid: 22272748.
  • Chen DT, Hsu YL, Fulp WJ, Coppola D, Haura EB, Yeatman TJ, Cress WD. Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer. J Natl Cancer Inst. 2011 Dec;103(24):1859-1870. Pubmedid: 22157961. Pmcid: PMC3243673.
  • Tang H, Yan C, Cao J, Sarma JV, Haura EB, Wu M, Gao H. An essential role for Stat3 in regulating IgG immune complex-induced pulmonary inflammation. FASEB J. 2011 Dec;25(12):4292-4300. Pubmedid: 21859893. Pmcid: PMC3236634.
  • Simon GR, Ilaria RL, Sovak MA, Williams CC, Haura EB, Cleverly AL, Sykes AK, Wagner MM, de Alwis DP, Slapak CA, Miller MA, Spriggs DR. A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors. Cancer Chemother Pharmacol. 2011 Nov;68(5):1233-1241. Pubmedid: 21431416. Pmcid: PMC3215883.
  • Pillai S, Rizwani W, Li X, Rawal B, Nair S, Schell MJ, Bepler G, Haura E, Coppola D, Chellappan S. ID1 facilitates the growth and metastasis of non-small cell lung cancer in response to nicotinic acetylcholine receptor and epidermal growth factor receptor signaling. Mol Cell Biol. 2011 Oct;31(14):3052-3067. Pubmedid: 21606196. Pmcid: PMC3133413.
  • Yoshida T, Haura EB. The Potential Benefits of BIM in the Further Pursuit of Biomarker Discovery in Cancer Therapeutics. Cancer Discov. 2011 Sep;1(4):289-290. Pubmedid: 22586609.
  • Remily-Wood ER, Liu RZ, Xiang Y, Chen Y, Thomas CE, Rajyaguru N, Kaufman LM, Ochoa JE, Hazlehurst L, Pinilla-Ibarz J, Lancet J, Zhang G, Haura E, Shibata D, Yeatman T, Smalley KS, Dalton WS, Huang E, Scott E, Bloom GC, Eschrich SA, Koomen JM. A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer. Proteomics Clin Appl. 2011 Aug;5(7-8):383-396. Pubmedid: 21656910. Pmcid: PMC3530891.
  • Brazelle W, Kreahling JM, Gemmer J, Ma Y, Cress WD, Haura E, Altiok S. Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells. PLoS One. 2011 Jul;5(12):e14335. Pubmedid: 21179472. Pmcid: PMC3001870.
  • Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, Brace LE, Woods BA, Lin W, Zhang J, Deng X, Lim SM, Heynck S, Peifer M, Simard JR, Lawrence MS, Onofrio RC, Salvesen HB, Seidel D, Zander T, Heuckmann JM, Soltermann A, Moch H, Koker M, Leenders F, Gabler F, Querings S, Ansén S, Brambilla E, Brambilla C, Lorimier P, Brustugun OT, Helland A, Petersen I, Clement JH, Groen H, Timens W, Sietsma H, Stoelben E, Wolf J, Beer DG, Tsao MS, Hanna M, Hatton C, Eck MJ, Janne PA, Johnson BE, Winckler W, Greulich H, Bass AJ, Cho J, Rauh D, Gray NS, Wong KK, Haura EB, Thomas RK, Meyerson M. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 2011 Jun;1(1):78-89. Pubmedid: 22328973. Pmcid: PMC3274752.
  • Song L, Rawal B, Nemeth JA, Haura EB. JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling. Mol Cancer Ther. 2011 Mar;10(3):481-494. Pubmedid: 21216930. Pmcid: PMC4084653.
  • Machida K, Eschrich S, Li J, Bai Y, Koomen J, Mayer BJ, Haura EB. Characterizing tyrosine phosphorylation signaling in lung cancer using SH2 profiling. PLoS One. 2011 Mar;5(10):e13470. Pubmedid: 20976048. Pmcid: PMC2957407.
  • Bepler G, Dilling TJ, Wagner H, Hazelton T, Williams C, Chen DT, Greenberg H, Walsh F, Simon G, Tanvetyanon T, Chiappori A, Haura E, Stevens C. Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage III non-small cell lung cancer. J Thorac Oncol. 2011 Mar;6(3):553-558. Pubmedid: 21289520.
  • Dasgupta P, Rizwani W, Pillai S, Davis R, Banerjee S, Hug K, Lloyd M, Coppola D, Haura E, Chellappan SP. ARRB1-mediated regulation of E2F target genes in nicotine-induced growth of lung tumors. J Natl Cancer Inst. 2011 Feb;103(4):317-333. Pubmedid: 21212384. Pmcid: PMC3039728.
  • Zhang G, Fang B, Liu RZ, Lin H, Kinose F, Bai Y, Oguz U, Remily-Wood ER, Li J, Altiok S, Eschrich S, Koomen J, Haura EB. Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivity. J Proteome Res. 2011 Jan;10(1):305-319. Pubmedid: 21080693. Pmcid: PMC3050523.
  • Haura EB, Müller A, Breitwieser FP, Li J, Grebien F, Colinge J, Bennett KL. Using iTRAQ combined with tandem affinity purification to enhance low-abundance proteins associated with somatically mutated EGFR core complexes in lung cancer. J Proteome Res. 2011 Jan;10(1):182-190. Pubmedid: 20945942. Pmcid: PMC3017669.
  • Haura EB, Sommers E, Song L, Chiappori A, Becker A. A pilot study of preoperative gefitinib for early-stage lung cancer to assess intratumor drug concentration and pathways mediating primary resistance. J Thorac Oncol. 2010 Nov;5(11):1806-1814. Pubmedid: 20881637.
  • Ren Y, Chen Z, Chen L, Fang B, Win-Piazza H, Haura E, Koomen JM, Wu J. Critical role of Shp2 in tumor growth involving regulation of c-Myc. Genes Cancer. 2010 Oct;1(10):994-1007. Pubmedid: 21442024.
  • Yoshida T, Zhang G, Haura EB. Targeting epidermal growth factor receptor: central signaling kinase in lung cancer. Biochem Pharmacol. 2010 Sep;80(5):613-623. Pubmedid: 20519133.
  • Fang B, Haura EB, Smalley KS, Eschrich SA, Koomen JM. Methods for investigation of targeted kinase inhibitor therapy using chemical proteomics and phosphorylation profiling. Biochem Pharmacol. 2010 Sep;80(5):739-747. Pubmedid: 20361944. Pmcid: PMC2995952.
  • Tanvetyanon T, Robinson L, Sommers KE, Haura E, Kim J, Altiok S, Bepler G. Relationship between Tumor Size and Survival among Patients with Resection of Multiple Synchronous Lung Cancers. J Thorac Oncol. 2010 Jul;5(7):1018-1024. Pubmedid: 20453687.
  • Rothschild SI, Gautschi O, Haura EB, Johnson FM. Src inhibitors in lung cancer: current status and future directions. Clin Lung Cancer. 2010 Jul;11(4):238-242. Pubmedid: 20630825.
  • Haura EB, Camidge DR, Reckamp K, Chiappori A, Johnson F, Herbst R, Wong K, Carbone D. Molecular origins of lung cancer: prospects for personalized prevention and therapy. J Thorac Oncol. 2010 Jun;5(6 Suppl 3):S207-S213. Pubmedid: 20502275.
  • Haura EB, Ricart AD, Larson TG, Stella PJ, Bazhenova L, Miller VA, Cohen RB, Eisenberg PD, Selaru P, Wilner KD, Gadgeel SM. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res. 2010 Apr;16(8):2450-2457. Pubmedid: 20332327.
  • Li J, Rix U, Fang B, Bai Y, Edwards A, Colinge J, Bennett KL, Gao J, Song L, Eschrich S, Superti-Furga G, Koomen J, Haura EB. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol. 2010 Apr;6(4):291-299. Pubmedid: 20190765. Pmcid: PMC2842457.
  • Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, Gray J, Litschauer S, Tetteh L, Neuger A, Song L, Rawal B, Schell MJ, Bepler G. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol. 2010 Mar;28(8):1387-1394. Pubmedid: 20142592. Pmcid: PMC3040065.
  • Davis R, Rizwani W, Banerjee S, Kovacs M, Haura E, Coppola D, Chellappan S. Nicotine promotes tumor growth and metastasis in mouse models of lung cancer. PLoS One. 2010 Mar;4(10):e7524. Pubmedid: 19841737. Pmcid: PMC2759510.
  • Kim LC, Rix U, Haura EB. Dasatinib in solid tumors. Expert Opin Investig Drugs. 2010 Mar;19(3):415-425. Pubmedid: 20113198.
  • Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol. 2009 Oct;6(10):587-595. Pubmedid: 19787002.
  • Gao J, Zheng Z, Rawal B, Schell MJ, Bepler G, Haura EB. Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells. Cancer Biol Ther. 2009 Sep;8(17):1671-1679. Pubmedid: 19633423. Pmcid: PMC3839311.
  • Gao J, McConnell MJ, Yu B, Li J, Balko JM, Black EP, Johnson JO, Lloyd MC, Altiok S, Haura EB. MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion. Int J Oncol. 2009 Aug;35(2):337-345. Pubmedid: 19578748. Pmcid: PMC4098131.
  • Dasgupta P, Rizwani W, Pillai S, Kinkade R, Kovacs M, Rastogi S, Banerjee S, Carless M, Kim E, Coppola D, Haura E, Chellappan S. Nicotine induces cell proliferation, invasion and epithelial-mesenchymal transition in a variety of human cancer cell lines. Int J Cancer. 2009 Jan;124(1):36-45. Pubmedid: 18844224. Pmcid: PMC2826200.
  • Lu D, Liu RZ, Izumi V, Fenstermacher D, Haura EB, Koomen J, Eschrich SA. IPEP: an in silico tool to examine proteolytic peptides for mass spectrometry. Bioinformatics. 2009 Jan;24(23):2801-2802. Pubmedid: 18842605.
  • Koomen JM, Haura EB, Bepler G, Sutphen R, Remily-Wood ER, Benson K, Hussein M, Hazlehurst LA, Yeatman TJ, Hildreth LT, Sellers TA, Jacobsen PB, Fenstermacher DA, Dalton WS. Proteomic contributions to personalized cancer care. Mol Cell Proteomics. 2008 Dec;7(10):1780-1794. Pubmedid: 18664563. Pmcid: PMC2559938.
  • Bepler G, Sommers KE, Cantor A, Li X, Sharma A, Williams C, Chiappori A, Haura E, Antonia S, Tanvetyanon T, Simon G, Obasaju C, Robinson LA. Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol. 2008 Oct;3(10):1112-1118. Pubmedid: 18827606. Pmcid: PMC2639211.
  • Simon GR, Extermann M, Chiappori A, Williams CC, Begum M, Kapoor R, Haura EB, Ismail-Khan R, Schell MJ, Antonia SJ, Bepler G. Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older. Cancer. 2008 May;112(9):2021-2029. Pubmedid: 18300255.
  • Li J, Viallet J, Haura EB. A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells. Cancer Chemother Pharmacol. 2008 Mar;61(3):525-534. Pubmedid: 17505826.
  • Chiappori AA, Haura E, Rodriguez FA, Boulware D, Kapoor R, Neuger AM, Lush R, Padilla B, Burton M, Williams C, Simon G, Antonia S, Sullivan DM, Bepler G. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. Clin Cancer Res. 2008 Mar;14(5):1464-1469. Pubmedid: 18316570.
  • Edwards A, Li J, Atadja P, Bhalla K, Haura EB. Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. Mol Cancer Ther. 2007 Sep;6(9):2515-2524. Pubmedid: 17876048.
  • Simon G, Sharma A, Li X, Hazelton T, Walsh F, Williams C, Chiappori A, Haura E, Tanvetyanon T, Antonia S, Cantor A, Bepler G. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol. 2007 Jul;25(19):2741-2746. Pubmedid: 17602079.
  • de Lima Lopes G, Chiappori A, Simon G, Haura E, Sullivan D, Antonia S, Langevin M, Lush R, Rocha-Lima CM. Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors: preliminary evidence of activity in small cell and neuroendocrine carcinomas. Cancer. 2007 Apr;109(7):1413-1419. Pubmedid: 17326096.
  • Li J, Yu B, Song L, Eschrich S, Haura E. Effects of IFN-gamma and Stat1 on gene expression, growth, and survival in non-small cell lung cancer cells. J Interferon Cytokine Res. 2007 Mar;27(3):209-220. Pubmedid: 17348819.
  • Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med. 2007 Feb;356(8):800-808. Pubmedid: 17314339.
  • Balko J, Potti A, Saunders C, Stromberg A, Haura E, Black E. Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors. BMC Genomics. 2006 Dec;7:289. Pubmedid: 17096850. Pmcid: PMC1660550.
  • Dasgupta P, Rastogi S, Pillai S, Ordonez-Ercan D, Morris M, Haura E, Chellappan S. Nicotine induces cell proliferation by beta-arrestin-mediated activation of Srcand Rb-Raf-1 pathways. J Clin Invest. 2006 Aug;116(8):2208-2217. Pubmedid: 16862215.
  • Haura EB. SRC and STAT pathways. J Thorac Oncol. 2006 Jun;1(5):403-405. Pubmedid: 17409890.
  • Song L, Morris M, Bagui T, Lee FY, Jove R, Haura EB. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006 Jun;66(11):5542-5548. Pubmedid: 16740687.
  • Haura E. Is repetitive wounding and bone marrow-derived stem cell mediated-repair an etiology of lung cancer development and dissemination. Med Hypotheses. 2006 May;67(4):951-6. Pubmedid: 16714090.
  • Dasgupta P, Kinkade R, Joshi B, Decook C, Haura E, Chellappan S. Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. Proc Natl Acad Sci U S A. 2006 Apr;103(16):6332-6337. Pubmedid: 16601104. Pmcid: PMC1458878.
  • Haura E, Livingston S, Coppola D. Autocrine interleukin-6/interleukin-6 receptor stimulation in non-small-cell lung cancer. Clin Lung Cancer. 2006 Jan;7(4):273-275. Pubmedid: 16512982.
  • Haura EB, Zheng Z, Song L, Cantor A, Bepler G. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res. 2005 Dec;11(23):8288-8294. Pubmedid: 16322287.
  • Chiappori A, Simon G, Williams C, Haura E, Rocha-Lima C, Wagner H, Bepler G, Antonia S. Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer. Oncology-Basel. 2005 Sep;68(4-6):382-390. Pubmedid: 16020967.
  • Zheng Z, Bepler G, Cantor A, Haura EB. Small tumor size and limited smoking history predicts activated epidermal growth factor receptor in early-stage non-small cell lung cancer. Chest. 2005 Jul;128(1):308-316. Pubmedid: 16002951.
  • Freeman S, Bepler G, Haura E, Sutphen R, Cress W. Re: Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia. J Natl Cancer Inst. 2005 Jul;97(14):1088-1089. Pubmedid: 16030308.
  • Haura E, Turkson J, Jove R. Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol. 2005 Jun;2(6):315-324. Pubmedid: 16264989.
  • Dauer D, Ferraro B, Song L, Yu B, Mora L, Buettner R, Enkemann S, Jove R, Haura E. Stat3 regulates genes common to both wound healing and cancer. Oncogene. 2005 May;24(21):3397-3408. Pubmedid: 15735721.
  • Ferraro B, Bepler G, Sharma S, Cantor A, Haura E. EGR1 predicts PTEN and survival in patients with non-small-cell lung cancer. J Clin Oncol. 2005 Mar;23(9):1921-1926. Pubmedid: 15774784.
  • Song L, Coppola D, Livingston S, Cress D, Haura EB. Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer Biol Ther. 2005 Mar;4(3):267-276. Pubmedid: 15753661.
  • Bepler G, Zheng Z, Gautam A, Sharma S, Cantor A, Cress W, Kim Y, Rosell R, McBride C, Robinson L, Sommers E, Haura E. Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. Lung Cancer. 2005 Feb;47(2):183-192. Pubmedid: 15639717.
  • Haura EB, Cress WD, Chellappan S, Zheng Z, Bepler G. Antiapoptotic signaling pathways in non-small-cell lung cancer: biology and therapeutic strategies. Clin Lung Cancer. 2004 Sep;6(2):113-122. Pubmedid: 15476597.
  • D'Amato G, Rocha Lima C, Mahany JJ, Muro-Cacho C, Haura EB. Neutropenic enterocolitis (typhilitis) associated with docetaxel therapy in a patient with non-small-cell lung cancer: case report and review of literature. Lung Cancer. 2004 Jun;44(3):381-390. Pubmedid: 15140552.
  • Turkson J, Kim JS, Zhang S, Yuan J, Huang M, Glenn M, Haura E, Sebti S, Hamilton AD, Jove R. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther. 2004 Mar;3(3):261-269. Pubmedid: 15026546.
  • Hauser P, Ma L, Agrawal D, Haura E, Cress WD, Pledger WJ. Efficient down-regulation of cyclin A-associated activity and expression in suspended primary keratinocytes requires p21(Cip1). Mol Cancer Res. 2004 Feb;2(2):96-104. Pubmedid: 14985466.
  • Howard B, Zheng Z, Campa M, Wang M, Sharma A, Haura E, Herndon JE 2nd, Fitzgerald M, Bepler G, Patz EF J. Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer. Lung Cancer. 2004;46(3):313-323. Pubmedid: 15541816.
  • Bepler G, Sharma S, Cantor A, Gautam A, Haura E, Simon G, Sharma A, Sommers E, Robinson L. RRM1 and PTEN as prognostic parameters for overall and disease-free survival inpatients with non-small-cell lung cancer. J Clin Oncol. 2004;22(10):1878-1885. Pubmedid: 15143080.
  • Haura EB, Sotomayor E, Antonia SJ. Gene therapy for lung cancer. Mol Biotechnol. 2003 Oct;25(2):139-148. Pubmedid: 14526124.
  • Bagui TK, Mohapatra S, Haura E, Pledger WJ. P27Kip1 and p21Cip1 are not required for the formation of active D cyclin-cdk4 complexes. Mol Cell Biol. 2003 Oct;23(20):7285-7290. Pubmedid: 14517297. Pmcid: PMC230308.
  • Song L, Turkson J, Karras JG, Jove R, Haura EB. Activation of Stat3 by receptor tyrosine kinases regulates survival in human non-small cell carcinoma. Oncogene. 2003 Jul;22(27):4150-4165. Pubmedid: 12833138.
  • Ma Y, Cress WD, Haura EB. Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1. Mol Cancer Ther. 2003 Jan;2(1):73-81. Pubmedid: 12533675.
  • Haura EB, Sotomayor E, Antonia SJ. Gene therapy for lung cancer. An introduction. Methods Mol Med. 2003;75:529-543. Pubmedid: 12407762.
  • Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Heller R, Ellis LM, Karras J, Bromberg J, Pardoll D, Jove R, Yu H. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002 Mar;21(13):2000-2008. Pubmedid: 11960372.
  • Croxton R, Ma Y, Song L, Haura E, Cress W. Direct repression of the Mcl-1 promoter by E2F1. Oncogene. 2002 Feb;21(9):1359-1369. Pubmedid: 11857079.
  • Sarries C, Haura E, Roig B, Taron M, Abad A, Scagliotti G, Rosell R. Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer. Pharmacogenomics. 2002;3(6):763-780. Pubmedid: 12437479.
  • Haura E. Management of advanced non-small cell lung cancer: current trends. Curr Opin Pulm Med. 2002;8(4):251-256. Pubmedid: 12055385.
  • Haura E, Winden M, Proia A, Trotter J. Fulminant hepatic failure due to disseminated adenovirus infection in a patient with chronic lymphocytic leukemia. Cancer Control. 2002;9(3):248-253. Pubmedid: 12060822.
  • Turkson J, Ryan D, Kim J, Zhang Y, Chen Z, Haura E, Laudano A, Sebti S, Hamilton A, Jove R. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem. 2001;276(48):45443-45455. Pubmedid: 11579100.
  • Haura E. Treatment of advanced non-small cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies. Cancer Control. 2001;8(4):326-336. Pubmedid: 11483886.
  • Sears R, Nuckolls F, Haura E, Nevins J. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 2000;14(19):2501-2514. Pubmedid: 11018017.
  • Simon G, Ruckdeschel J, Williams C, Cantor A, Antonia S, Haura E, Rocha C, Chiappori A, Wagner H, Robinson L, Sommers E, Alberts M, Bepler G. Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution. Cancer Control. 10(5):388-395. Pubmedid: 14581894.
TOOLS:   Font Size small font resizer separator font resizer separator big font resizer
 |  Site Map  |  Privacy Policy  |  Terms and Conditions